Clinical Evidence Supporting Wegovy for Weight Loss Wegovy's approval rests primarily on the STEP clinical trial program
Discussion Using data from the STEP 1 and STEP 2 phase 3 trials, we found broad effects from subcutaneous semaglutide treatment in people with overweight or obesity (with and without T2D) on the circulating proteome compared with placebo
Structural insights into the activation of GLP-1R by a small molecule agonist
To put that into more concrete terms: on the 0 to 18 CDR-SB scale, lecanemab, a monoclonal antibody thats not approved on the NHS (because of cost) but is approved by the FDA, showed a 0.45-point advantage at 18 months, which is about 27% slower than placebo
I started with a smaller dosage to make sure I don't have side effects or have them at a minimum
If you experience lightheadedness or leg cramps , these may relate to reduced caloric intake rather than the medication itself